xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

197

ICAR SINONASAL TUMORS

TABLE XXI.B.1 Evidence for outcomes for IP-SCC versus DN-SCC.

Clinical endpoints 1. OS 2. DFS 3. Distant

Study

Year LOE Study design Study groups

Conclusion

Li et al. 1119

1. DN-SCC 5-year OS 55.4%, DFS 50.1%; IP-SCC 5-year OS 63.3%, DFS45.4% 2. Metachronous tumors had better prognosis than synchronous tumor and DN-SCC 3. DN-SCC demonstrated increased incidence of distant metastasis 1. No significant difference in DSS in T1, T2, and T3 tumors 2. T4 DN-SCC had better DSS than those with IP-SCC 1. No significant difference in OS orDFS 2. Similar survival outcomes; IP-SCC had a higher local failure rate 1. DN-SCC 5-year OS 39.5%, DSS 52.8% 2. IP-SCC 5-year OS 58.3%, DSS 61.5% 1. DN-SCC 5-year OS 69%, DSS 72.9%; IP-SCC 5-year OS 84.6%, DSS89.6% 2. Early-stage IP-SCC had better DSS than DN-SCC 1. DN-SCC 5-year OS 65.8%, DFS 60.3% 2. IP-SCC 5-year OS 77%, DFS 62.6% 1. DN-SCC 5-year OS 75.1%, DFS 62%; IP-SCC 5-year OS 86%, DFS 62% 2. IP-SCC has no prognostic significance

2021

4

Retrospective case series

DN-SCC( n = 84), IP-SCC( n = 89)

metastasis

Yasumatsu et al. 1117

2020 4

Retrospective case series

DN-SCC( n = 94), IP-SCC( n = 23)

1. DSS 2. Recurrence rates 1. OS 2. DFS 3. Local failure rate 4. Nodal failure rate 5. Distant metastasis

Quanet al. 1118

2020 4

Retrospective case series

DN-SCC( n = 123), IP-SCC( n = 39)

Yuet al. 1115

2017 4

Retrospective case series

DN-SCC( n = 65), IP-SCC( n = 21)

1. OS 2. DSS

Yanet al. 1110

2017 4

Retrospective case series

DN-SCC( n = 28), IP-SCC( n = 38)

1. OS 2. DSS

Loboet al. 1116

2017 4

Retrospective case series

DN-SCC( n = 88), IP-SCC( n = 29)

1. OS 2. DFS

deAlmeida et al. 130

2015 4

Retrospective case series

DN-SCC( n = 21), IP-SCC( n = 13)

1. OS 2. DFS

Lavertu et al. 1111 1. DN-SCC 5-year OS 29.8% 2. IP-SCC 5-year OS 70% Abbreviations: DFS, disease-free survival; DN-SCC, de novo squamous cell carcinoma; IP-SCC, inverted papilloma associated squamous cell carcinoma; OS, overall survival. 1989 4 Retrospective case series DN-SCC( n = 43), IP-SCC( n = 11) OS

The majority of IP-SCCs harbor EGFR mutations; these activating mutations are typically frame-preserving exon 20 indels, but exon 6 and exon 19 mutations have also been reported. 659,660,672,1131,1138 EGFR exon 20 mutations have described in minor subsets of lung adenocarci noma, glioma, and urothelial carcinoma but are otherwise rare in human malignancies. 653 As such, the presence of an EGFR exon 20 mutation in a sinonasal carcinoma is essentially diagnostic of IP-SCC, even without clin

ical or pathologic evidence of IP, and molecular-based estimates suggest that IP-SCC represent 15%–30% of all sinonasal SCC. 672,1138,1139 Tumors without EGFR muta tions usually demonstrate low-risk HPV infection, and high-risk HPV infection is uncommon (or not observed) in contemporary IP-SCC cohorts with expert pathol ogy review. 660,662,666,667,672,1138 Shared EGFR mutations or low-risk HPV genotypes are present in the associated metachronous or synchronous IP, indicating that IPs are